ADL Amdl,

TUSTIN, Calif., Feb. 21 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that its CEO Gary Dreher will present a corporate overview at the Roth Capital Partners 19th Annual Conference in Dana Point, California, on Thursday, February 22, 2007, at 11 a.m. Pacific Standard Time. Mr. Dreher will tell the conference about recent successes for Jade Pharmaceuticals, AMDL's wholly-owned pharmaceutical manufacturing subsidiary in China, which include setting up production and applying for SFDA (China State Food and Drug Administration) approval to market Docetaxel, an anti-cancer drug that interferes with the growth of cancer cells and is extremely useful because it can treat a broad spectrum of cancers, including breast cancer, non-small cell lung cancer, stomach cancer and prostate cancer. The Company also recently announced the introduction in China of Ondansetron Hydrochloride, which is prescribed for nausea caused by chemotherapy, radiation and other conditions, and the introduction of newly licensed products Lomefloxacin Aspartate and Levofloxacin, which are broad spectrum antibiotics. "The addition of these products should significantly increase sales and profits in 2007," said Mr. Dreher. Through its subsidiaries, Jade Pharmaceuticals currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice standards. "We believe the Roth investors will be very interested in our achievements in the world's fastest growing pharmaceutical market," Mr. Dreher said. Roth Capital Partners, LLC, a full service investment bank, annually hosts the largest and most prestigious small-cap growth stock conference in the U.S. In excess of 1,000 institutional investors have attended previous conferences. "Roth is a leader and innovator in the small and micro-cap markets and we are pleased by the opportunity to present at its conference," said Mr. Dreher. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. About AMDL AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at http://www.amdl.com/. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright